CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.
The firm plans to use the funding to expand commercial sales efforts, advance CDx partnerships, build its regulatory infrastructure, and explore new R&D avenues.
The firm will provide product enhancement and clinical lab services, including comprehensive tumor profiling using proprietary cell-based products and services.
The firm said the one-for-five reverse split will help address a looming delisting from the Nasdaq Capital Market by boosting the bid price per share above $1.00.
Several academic and commercial groups are developing clinical cell-based noninvasive prenatal tests, which could eventually compete with current cell-free NIPTs.
NEW YORK (GenomeWeb News) – The University Medical Center at Johannes Gutenberg University Mainz in Germany (JGU) announced today separate deals to build out its capabilities in neuroscience research.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
